Exelixis Inc has a consensus price target of $28, established from looking at the 55 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Stifel, and Barclays on February 7, 2024, February 2, 2024, and January 30, 2024. With an average price target of $26 between RBC Capital, Stifel, and Barclays, there's an implied 8.97% upside for Exelixis Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/07/2024 | EXEL | Buy Now | Exelixis | $23.86 | 17.35% | RBC Capital | Gregory Renza | $26 → $28 | Maintains | Outperform | Get Alert |
02/02/2024 | EXEL | Buy Now | Exelixis | $23.86 | 4.78% | Stifel | Stephen Willey | $23 → $25 | Maintains | Hold | Get Alert |
01/30/2024 | EXEL | Buy Now | Exelixis | $23.86 | 4.78% | Barclays | Peter Lawson | $24 → $25 | Maintains | Overweight | Get Alert |
12/19/2023 | EXEL | Buy Now | Exelixis | $23.86 | 13.16% | BTIG | Kaveri Pohlman | → $27 | Initiates | → Buy | Get Alert |
12/15/2023 | EXEL | Buy Now | Exelixis | $23.86 | 29.92% | Citigroup | David Lebowitz | → $31 | Initiates | → Buy | Get Alert |
12/14/2023 | EXEL | Buy Now | Exelixis | $23.86 | 13.16% | JMP Securities | Silvan Tuerkcan | → $27 | Reiterates | Market Outperform → Market Outperform | Get Alert |
12/13/2023 | EXEL | Buy Now | Exelixis | $23.86 | 8.97% | RBC Capital | Gregory Renza | → $26 | Reiterates | Outperform → Outperform | Get Alert |
11/13/2023 | EXEL | Buy Now | Exelixis | $23.86 | 13.16% | JMP Securities | Silvan Tuerkcan | → $27 | Reiterates | Market Outperform → Market Outperform | Get Alert |
11/02/2023 | EXEL | Buy Now | Exelixis | $23.86 | -3.6% | Morgan Stanley | Jefferson Harralson | $22 → $23 | Maintains | Equal-Weight | Get Alert |
10/11/2023 | EXEL | Buy Now | Exelixis | $23.86 | 25.73% | Guggenheim | Michael Schmidt | → $30 | Reiterates | Buy → Buy | Get Alert |
09/26/2023 | EXEL | Buy Now | Exelixis | $23.86 | 17.35% | HC Wainwright & Co. | Robert Burns | → $28 | Initiates | → Buy | Get Alert |
09/25/2023 | EXEL | Buy Now | Exelixis | $23.86 | 25.73% | Guggenheim | Michael Schmidt | $27 → $30 | Maintains | Buy | Get Alert |
09/13/2023 | EXEL | Buy Now | Exelixis | $23.86 | -3.6% | Stifel | Stephen Willey | → $23 | Reiterates | Hold → Hold | Get Alert |
09/13/2023 | EXEL | Buy Now | Exelixis | $23.86 | 34.12% | Truist Securities | Asthika Goonewardene | → $32 | Reiterates | Buy → Buy | Get Alert |
08/22/2023 | EXEL | Buy Now | Exelixis | $23.86 | 21.54% | Oppenheimer | Jay Olson | $25 → $29 | Maintains | Outperform | Get Alert |
08/22/2023 | EXEL | Buy Now | Exelixis | $23.86 | 13.16% | JMP Securities | Silvan Tuerkcan | $24 → $27 | Maintains | Outperform | Get Alert |
08/08/2023 | EXEL | Buy Now | Exelixis | $23.86 | -24.56% | SVB Leerink | Christopher Liu | → $18 | Initiates | → Market Perform | Get Alert |
08/03/2023 | EXEL | Buy Now | Exelixis | $23.86 | 0.59% | Barclays | Peter Lawson | $25 → $24 | Maintains | Overweight | Get Alert |
08/02/2023 | EXEL | Buy Now | Exelixis | $23.86 | -3.6% | Stifel | Stephen Willey | $21 → $23 | Maintains | Hold | Get Alert |
The latest price target for Exelixis (NASDAQ: EXEL) was reported by RBC Capital on February 7, 2024. The analyst firm set a price target for $28.00 expecting EXEL to rise to within 12 months (a possible 17.35% upside). 28 analyst firms have reported ratings in the last year.
The latest analyst rating for Exelixis (NASDAQ: EXEL) was provided by RBC Capital, and Exelixis maintained their outperform rating.
There is no last upgrade for Exelixis.
There is no last downgrade for Exelixis.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exelixis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exelixis was filed on February 7, 2024 so you should expect the next rating to be made available sometime around February 7, 2025.
While ratings are subjective and will change, the latest Exelixis (EXEL) rating was a maintained with a price target of $26.00 to $28.00. The current price Exelixis (EXEL) is trading at is $23.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.